Renal Tumour Imaging Using MRI

NCT07173140 — Not applicable, Active not recruiting, 30 participants, University College, London

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Two Site Pilot Study of Functional and Microstructural Imaging Using Magnetic Resonance Imaging in Patients With Renal Tumours

RegistryNCT07173140, acronym RIM
StatusActive not recruiting
PhaseNot applicable
Study typeInterventional; non randomized, parallel, masking: none, diagnostic
Enrollment30 (Actual)
SponsorUniversity College, London (Other); collaborators: Royal Free Hospital NHS Foundation Trust, University College London Hospitals
ConditionsRenal Cancer, MRI, Small Renal Mass, Kidney Cancers
InterventionsMRI (Diagnostic test)
Datesstart 2024-11-20, primary completion 2025-06-19, completion 2025-09-30 (estimated), first posted 2025-09-15, last updated 2025-09-15
Locations1 site in United Kingdom

Related Papers Related Patents Related Grants Related Experts
All trials for Renal Cancer All trials for MRI All trials of MRI

-Summary

This study investigates whether new types of MRI scans can tell the difference between different kidney tumours before surgery. Currently, imaging scans can detect kidney tumours and their size, but they aren't effective at determining the tumour type or its aggressiveness. Biopsies are an option, but they are invasive and may miss important cancerous cells. The aim is to use imaging to determine which tumours are aggressive so they can be treated early while avoiding unnecessary treatment of benign tumours.

Patients with small renal tumours (≤ 7 cm) who meet the other inclusion and exclusion criteria will be asked to have an additional MRI scan at University College London Hospital prior to surgery.

The imaging findings will be compared to the histology result from the removed tumour. In 10 patients the histology will be targeted to a specific location in the tumour based on the imaging. 10 patients will undergo a repeat MRI <14 d apart to test whether the MRI scans can give the same answer twice (the test repeatability).

The study is expected to run for 24 months and is funded by NIHR.

The chief investigator for the study is Dr Richard Hesketh (rhesketh@ucl.ac.uk).

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Histological characterisation of renal tumoursNo interventionHistological samples of ten patients with tumour histology will be retreived from the Royal Free Hospital Biobank. Slides will be stained using H\&E and CD34 and cell size, stromal space and vascularity will be estimated and used to inform diffusion weighted imaging models.
Comparison of microstructural MRI to histologyExperimentalDiagnostic Test: MRI10 patients with small renal tumours will undergo microstructural MRI. Following MRI the tumours will be surgically resected. The MRI will be co-registered with histology. The degree of correlation between the MRI and underlying histology will be determined.
Repeatability of MRI of small renal massesExperimentalDiagnostic Test: MRIThe repeatability of the MRI scan of the small renal mass will be determined by participants undergoing a repeat MRI examination shortly after the first (within 14 d) on the same scanner.
  • MRI (Diagnostic test): Participants undergo an additional MRI scan using novel MRI sequences

+Outcome measures

Primary outcomes

  • Diagnostic accuracy of proton density fat fraction (PDFF) to differentiate different histological subtypes of renal tumours. [1 year]: PDFF mean values will be calculated for each tumour in arms 2 and 3. Following surgery the means for each histological subtype will be calculated and tested for statistical significance.
  • Repeatability of proton density fat fraction (PDFF) measurements. [1 year]: Participants in arm 3 will undergo repeat scanning with a short time interval between scans. The repeatability of PDFF measurements will be assessed using within subject standard deviation, repeatability coefficients and Bland-Altman analysis.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Aged 18 and over
2. Confirmed renal tumour ≤ 7 cm planned for surgical resection
3. Willing and able to provide written informed consent
4. Able to lie supine for the duration of an MRI

Exclusion Criteria:

1. Contraindication to MRI e.g., cardiac pacemaker
2. Contraindication to MR contrast agents
3. Pregnancy
4. Breastfeeding
5. Deranged renal function (eGFR <30) in the last three months.
6. Previous treatment of the renal tumour e.g., ablation, radiotherapy

+Locations (1)

FacilityCityCountryStatus
University College LondonLondonUnited Kingdom

+Publications

  • Results publication: Sen S, Smith L, Caselton L, Clemente J, Tran M, Punwani S, Atkinson D, Hesketh RL, Panagiotaki E. Dual deep learning approach for non-invasive renal tumour subtyping with VERDICT-MRI. Npj Imaging. 2026 Jan 6;4(1):2. doi: 10.1038/s44303-025-00135-6. PMID 41495369

+Study documents